Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)

Annexon (Nasdaq: ANNX) granted equity inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

Rhea-AI Summary

Annexon (Nasdaq: ANNX) granted equity inducement awards to two new non-executive employees under its 2022 Employment Inducement Award Plan, approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4). The employees received stock options for an aggregate 335,000 common shares.

The options have a ten-year term and an exercise price of $6.50 per share, equal to the July 15, 2026 closing price. Vesting occurs over four years: 25% after one year, then 1/48 of the shares monthly, subject to continued service.

News Explained

The release describes rights to purchase 335,000 common shares, with vesting and exercise terms, rather than reporting that those shares were issued; any ownership change therefore depends on later exercise.

Argus Jul 17 session 1 alert

-1.53% close to close 0.1x rel. volume Open Argus

Details

News Market Reaction – ANNX

$1.06B Market Cap

On Jul 17, the first trading day after this news, ANNX closed 1.53% below the previous close.

Data tracked by StockTitan Argus for the Jul 17 session.

Key Figures

Inducement option grants: 335,000 shares Exercise price: $6.50 per share Option term: 10 years +5 more

Inducement option grants

335,000 shares

Aggregate options to two new non-executive employees

Exercise price

$6.50 per share

Closing price on July 15, 2026 and grant date price

Option term

10 years

Term of employee stock options

Vesting period

4 years

Total vesting duration for the options

Initial vesting tranche

25% of shares

Vest on first anniversary of grant date

Ongoing vesting rate

1/48th of shares monthly

Monthly vesting after first anniversary, subject to service

Employees granted

2 employees

New non-executive hires receiving inducement options

Plan year

2022

Employment Inducement Award Plan vintage

Historical Context

5 past events · Latest: Jul 14

5 events

1. Jul 14

   Clinical trial update

   24h Move

   +17.1%

   Phase 2 ARCHER data presentation on vonaprument in geographic atrophy at ASRS.

2. Jun 16

   Inducement option grants

   24h Move

   +9.3%

   Inducement stock options for 705,000 shares at $4.64 under 2022 plan.

3. May 27

   Conference participation

   24h Move

   -2.4%

   CEO slated for fireside chats at two June 2026 healthcare conferences.

4. May 18

   Inducement option grants

   24h Move

   -1.0%

   Equity inducement options for 243,000 shares at $5.21 to new employees.

5. May 07

   1Q26 earnings report

   24h Move

   +3.1%

   Q1 2026 results with $225.0M cash and runway into second half 2027.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

nasdaq listing rule 5635(c)(4)

1 terms

nasdaq listing rule 5635(c)(4) regulatory

"approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4)."

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

BRISBANE, Calif., July 16, 2026 (GLOBE NEWSWIRE) -- Annexon, Inc. (Nasdaq: ANNX), a biopharmaceutical company advancing the next generation platform of targeted immunotherapies aimed at neuroinflammatory diseases that impact nearly 10 million people worldwide, today announced that it has granted inducement to two new non-executive employees under the terms of the 2022 Employment Inducement Award Plan. The equity awards were approved on July 12, 2026, in accordance with Nasdaq Listing Rule 5635(c)(4).

In the aggregate, the two new non-executive employees received options to purchase 335,000 shares of Annexon common stock. The options carry a ten-year term and an exercise price per share equal to $6.50, which was the closing price of Annexon’s common stock on July 15, 2026, the date of grant, and vest over 4 years, with 25% of the shares underlying the options vesting on the first anniversary of the grant date and an additional 1/48th of the shares vesting monthly thereafter, subject to each employee’s continued service through the applicable vesting dates.

About Annexon

Annexon Biosciences (Nasdaq: ANNX) is advancing the next generation platform of targeted immunotherapies for nearly 10 million people worldwide living with serious neuroinflammatory diseases. Our founding scientific approach focuses on C1q, the initiating molecule of a potent inflammatory pathway that when misdirected can lead to tissue damage and loss of function in a host of diseases. Our targeted therapies are designed to stop classical complement-driven neuroinflammation at its source to provide meaningful functional benefit and alter the course of disease. Annexon’s mission is to deliver game-changing therapies to patients so that they can live their best lives. To learn more visit annexonbio.com.

Investor Contact:

Joyce Allaire
LifeSci Advisors
jallaire@lifesciadvisors.com

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What stock options did Annexon (ANNX) grant to new employees on July 15, 2026?

Annexon granted stock options for an aggregate 335,000 common shares to two new non-executive employees. According to Annexon, these inducement awards were issued under the 2022 Employment Inducement Award Plan and are intended to attract and retain qualified personnel.

What is the exercise price and term of the new Annexon (ANNX) inducement stock options?

The new Annexon inducement options have an exercise price of $6.50 per share and a ten-year term. According to Annexon, the exercise price equals the closing price of its common stock on July 15, 2026, the grant date for these awards.

How do the Annexon (ANNX) inducement stock options granted in July 2026 vest?

The inducement options vest over four years, with 25% vesting on the first anniversary and the remaining 75% vesting monthly. According to Annexon, 1/48 of the shares vest each month thereafter, subject to each employee’s continued service.

Under which plan and rule were Annexon (ANNX) July 2026 inducement grants made?

The July 2026 inducement grants were made under Annexon’s 2022 Employment Inducement Award Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). According to Annexon, this rule allows equity awards as a material inducement to new employee hiring.

How many Annexon (ANNX) shares are covered by the July 2026 inducement option grants?

The July 2026 inducement option grants cover 335,000 shares of Annexon common stock in total. According to Annexon, these options were awarded in the aggregate to two new non-executive employees as part of their employment packages.